

DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall!

<https://marketpublishers.com/r/DC5539C349FEN.html>

Date: September 2011

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: DC5539C349FEN

Abstracts

Recent failures of Edoxaban's key competitor factor-Xa inhibitors from Japan - YM 150 (Astellas) and TAK-442 (Takeda), the closest candidate in Japan now is Xarelto (Bayer), which is still ~1 years away from hitting the market. Edoxaban is the first and only approved factor-Xa inhibitor in Japan for prevention of VTE, though Japanese VTE opportunity is not big but it will enhance investors' confidence regarding its global success where the opportunity is huge. Edoxaban is behind Xarelto in development for AF (~2 years). However, considering its high market potential it remains attractive as it is the only drug that has shown dose response in this class"

Contents

COMPANIES MENTIONED

DAIICHI SANKYO

I would like to order

Product name: DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall!

Product link: <https://marketpublishers.com/r/DC5539C349FEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DC5539C349FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970